Antibiotic Therapy of Methicillin-Resistant Staphylococcus Aureus in Critical Care

Critical Care Clinics

Volumn 24, Issue 2, 2008, Pages 249-260

  Tverdek, Frank P ^a,b   Crank, Christopher W ^b   Segreti, John ^b  

^a MIDWESTERN UNIVERSITY   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; LINEZOLID; OXACILLIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTHRALGIA; BACTERIAL COLONIZATION; BACTERIAL PNEUMONIA; BACTERIAL VIRULENCE; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG URINE LEVEL; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; INTENSIVE CARE; LOADING DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MYALGIA; NEPHROTOXICITY; OPTIC NEURITIS; OTOTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PRURITUS; RED NECK SYNDROME; REVIEW; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; THROMBOCYTOPENIA; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; CRITICAL CARE; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 41049100542     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2007.12.013     Document Type: Review

References (40)

1. Huang S.H., Rifas-Shaman S.L., Warren D.K., et al. Improving methicillin-resistant Staphylococcus aureus surveillance and reporting in intensive care units. J Infect Dis 195 (2007) 330-338
2. Wisplinghoff H., Bischoff T., Tallent S.M., et al. Nosocomial bloodstream infections in US hospitals: an analysis of 24,179 cases from prospective nationwide surveillance study. Clin Infect Dis 39 (2004) 309-317
3. Chastre J., and Jean-Yves F. Ventilator-associated pneumonia. Am J Respir Crit Care Med 165 (2002) 867-903
4. Wyllie D.H., Crook D.W., and Peto E.A. Mortality after Staphylococcus aureus bacteremia in two hospitals in Oxfordshire, 1997-2003: cohort study. BMJ 333 7562 (2006) 281-287
5. Centers for Disease Control (CDC). Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb Mortal Wkly Rep 51 26 (2002) 565-567
6. Fridkin S.K. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis 32 (2001) 108-115
7. Charles P.G., Ward P.B., Johnson P.D., et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 38 (2004) 448-451
8. Maor Y., Rahav G., Belausov N., et al. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in tertiary care center. J Clin Microbiol 45 (2007) 1511-1514
9. Steinkraus G., White R., and Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylcoccus aureus (VISA), vancomycin susceptibe clinical methicillin-resistant S aureus (MRSA) blood isolates from 2001-06. J Antimicrob Chemother 60 4 (2007) 788-794
10. CLSI. Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-MS16 (2006), CLSI, Wayne (PA)
11. Sakoulas G., Moise-Broder P.A., Schentag J., et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 42 6 (2004) 2398-2402
12. Moise P.A., Sakoulas G., Forrest A., et al. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 51 7 (2007) 2582-2586
13. Hidayat L.K., Hsu D.I., Quist R., et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections. Arch Intern Med 166 (2006) 2138-2144
14. Craig W. Pharmacokinetic/pharmacodynamic parameters: rationale for antimicrobial dosing of mice and men. Clin Infect Dis 26 1 (1998) 1-10
15. Levine D.P. Vancomycin: a history. Clin Infect Dis 42 Suppl 1 (2006) S5-S12
16. Feng-Yee C., Peacock J.E., Musher D.M., et al. Staphylococcus aureus bacteremia. Medicine 82 (2003) 333-339
17. Jeffres M.N., Isakow W., Doherty J.A., et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia. Chest 130 (2006) 947-955
18. American Thoracic Society/Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 (2005) 388-416
19. Wysocki M., Delatour F., Faurisson F., et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 45 9 (2001) 2460-2467
20. Fagon J.Y., Patrick H., Haas D.W., et al. Treatment of gram-positive nosocomial pneumonia. Am J Respir Crit Care Med 161 (2000) 753-762
21. Macgowan A.P. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with gram-positive infections. J Antimicrob Chemother 51 Suppl S2 (2003) ii17-ii25
22. Nasraway S.A., Shorr A.F., Kuter D.J., et al. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis 11 (2003) 1609-1616
23. Rubenstein E., Cammarata S., Oliphant T., et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 32 (2001) 402-412
24. Wunderink R.G., Cammarata S.K., Oliphant T.H., et al. Linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia: continuation of a randomized, double-blind, multicenter study. Clin Ther 25 (2003) 980-992
25. Wunderink R.G., Rello J., Cammarata S.K., et al. Linezolid versus vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124 5 (2003) 1789-1797
26. Kollef M.H., Rello J., Cammarata S.K., et al. Clinical cure and survival in gram-positive ventilator-associated pneumonia: retrospective analysis of the two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 30 (2004) 388-394
27. Shorr A.F., Kunkel M.J., and Kollef M. Linezolid versus vancomycin for Staphylcoccus aureus bacteremia: pooled analysis of randomized studies. J Antimicrob Chemother 56 (2005) 923-929
28. Benvenuto M., Benziger D.P., Yankelev S., et al. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 50 10 (2006) 3245-3249
29. Silverman J.A., Mortin L.I., VanPraagh A.D., et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191 (2005) 2149-2152
30. Fowler V.G., Boucher H.W., Corey R.G., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355 (2006) 653-665
31. Meagher A.K., Ambrose P.G., Grasela T.H., et al. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 41 (2005) S333-S340
32. Waites K.B., Duffy L.B., and Dowzicky M.J. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcyline antimicrobial. Antimicrob Agents Chemother 50 10 (2006) 3479-3484
33. Babinchak T., Ellis-Grosse E., Dartois N., et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 41 (2005) S354-S367
34. Ellis-Grosse E.J., Babinchak T., Dartois N., et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 41 (2005) S341-S353
35. Shafer J.J., Goff D.A., Stevenson K.B., et al. Early experience with tigecycline for ventilator associated pneumonia and bacteremia caused by multi-drug resistant Acinetobacter baumaunii. Pharmacotherapy 27 7 (2007) 980-987
36. Daley M.W., Riddle D.J., Ledeboer N.A., et al. Tigecycline for treatment of pneumonia and empyema caused by carbapenamase-producing Klebsiella pneumoniae. Pharmacotherapy 27 7 (2007) 1052-1057
37. Maroko R, Cooper A, Dukart G, et al. Results of phase 3 study comparing tigecycline regimen with an imipenem/cilastatin regimen in treatment of patients with hospital-acquired pneumonia. Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago (IL), September 16-20, 2007 (L-730).
38. Markowitz N., Quinn E.L., and Saravolatz L.D. Trimethoprim/sulfamethoxazole compared with vancomycin for the treatment of staphylococcus aureus infection. Ann Intern Med 117 5 (1992) 390-398
39. Weber J.T. Community acquired methicillin resistant Staphylococcus aureus. Clin Infect Dis 41 Suppl 4 (2005) S269-S272
40. Micek S.T., Dunne M., and Kollef M.H. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus. Chest 128 (2005) 2732-2738